Fenwick Represents MRL Ventures in VectorY’s $138 Million Series A Financing

Fenwick represented MRL Ventures, the therapeutics-focused corporate venture fund of Merck & Co., in its investment in VectorY’s $138 million Series A financing, one of the largest private biotech financings in Europe in 2023. The round was co-led by EQT Life Sciences and the Forbion Growth Opportunities Fund.

VectorY, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, will use the proceeds to support the clinical development of VTx-002, its lead vectorized antibody program targeting TDP-43 for the treatment of ALS. More information can be obtained from the company’s announcement.

The transaction was led by corporate partner Ian Goldstein and associates Serena Ward and Ty Chung.